Occupied with immunology and cancer, Merck KGaA hands off osteoarthritis drug to Novartis for €50M cash
By the time Merck KGaA published promising Phase II data for sprifermin — once tapped as a big prospect for the ailing R&D group …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
